Vitamin D Plus Fluticasone Propionate

有源比较器：Fluticasone Propionate plus Vitamin D3

Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season

药品：Vitamin D3

4000 IU once daily

药品：Fluticasone Propionate

200 mcg daily, intranasal

其他名称：

• 氟龙酶

安慰剂比较：Fluticasone Propionate plus Placebo

Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season

药品：Fluticasone Propionate

200 mcg daily, intranasal

其他名称：

• 氟龙酶

药品：Placebo

Placebo taken once daily

Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period

Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (e.g. itchy nose/throat) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24. The change from baseline for each day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group. A negative value indicates an improvement in symptoms.

Change From Baseline in Daytime Nasal Symptom Score (DNSS) Over 2 Week Randomized Treatment Period

Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (e.g. itchy nose/throat) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The DNSS was calculated as the sum of all scores for morning with a range of 0 to 12. The change from baseline for each day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group. A negative value indicates an improvement in daytime symptoms.